Mylan Inc. received the FDA approved for its generic version of the osteoarthritis and rheumatoid arthritis drug Nabumetone. The FDA approval allows Mylan to sell 500 milligram and 750 milligram tablets of Nabumetone. It is a nonsteroidal anti-inflammatory drug, which is a popular type of arthritis and inflammation treatment.

Read the full story here.

A study in the current issue of the European Journal Psychotherapy and Psychosomatics reveals that the association between psychiatric illness, in particular depression, and osteoporosis has been the subject of a growing body of research yielding various findings, although most identify some effect on bone.

In addition to medication-related processes and/or modifiable lifestyle factors associated with mood disturbances, endocrine and immune alteration secondary to depression may play a pathogenetic role in bone metabolism.

Additional longitudinal studies, with the advantage of temporal sequencing, remain to be conducted, as well as research into potential mechanisms surrounding the association. Nevertheless, the current findings are of clinical relevance, given the health burden of both depression and osteoporosis.

 Check out the full article in ScienceDaily.com.

Merck & Co.’s Fosamax (alendronate sodium) now has competition. Teva Pharmaceutical Industries Ltd. has received FDA approval for a generic version of Fosamax for osteoporosis treatment. The generic has been approved in doses of 5 mg, 10 mg, 35 mg, 40 mg and 70 mg. The company has marketing exclusivity for 180 days and plans to commence shipment of the drug immediately.